Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lin Shen

Showing results (1471-1480 of 1,553) with videos related to

Pageof 156
Sort By:
Scientific Reports|May 21, 2017
Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumorsYu-Li Song, Run Yu, Xin-Wei Qiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society SystemsGuopei Luo, Ammar Javed, Jonathan R Strosberg, et al.
Molecular Psychiatry|June 6, 2018
The ProNGF/p75NTR pathway induces tau pathology and is a therapeutic target for FTLD-tauLin-Lin Shen, Noralyn B Mañucat-Tan, Shi-Hao Gao, et al.
Journal of Gastroenterology and Hepatology|January 5, 2020
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trialJianming Xu, Rui-Hua Xu, Shukui Qin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2023
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649Markus Moehler, Hong Xiao, Steven I Blum, et al.
Nature Medicine|March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trialKohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
Nature Medicine|July 31, 2023
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialManish A Shah, Kohei Shitara, Jaffer A Ajani, et al.
Thoracic Cancer|July 25, 2018
Expert consensus on image-guided radiofrequency ablation of pulmonary tumors: 2018 editionBao-Dong Liu, Xin Ye, Wei-Jun Fan, et al.
Chinese Journal of Cancer|December 24, 2017
Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trialRui-Hua Xu, Lin Shen, Ke-Ming Wang, et al.
The Lancet. Oncology|April 20, 2023
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 studyJianming Xu, Ken Kato, Eric Raymond, et al.
Pageof 156

Showing results (1471-1480 of 1,553) with videos related to

Sort By:
Pageof 156
Scientific Reports|May 21, 2017
Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumorsYu-Li Song, Run Yu, Xin-Wei Qiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society SystemsGuopei Luo, Ammar Javed, Jonathan R Strosberg, et al.
Molecular Psychiatry|June 6, 2018
The ProNGF/p75NTR pathway induces tau pathology and is a therapeutic target for FTLD-tauLin-Lin Shen, Noralyn B Mañucat-Tan, Shi-Hao Gao, et al.
Journal of Gastroenterology and Hepatology|January 5, 2020
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trialJianming Xu, Rui-Hua Xu, Shukui Qin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2023
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649Markus Moehler, Hong Xiao, Steven I Blum, et al.
Nature Medicine|March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trialKohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
Nature Medicine|July 31, 2023
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialManish A Shah, Kohei Shitara, Jaffer A Ajani, et al.
Thoracic Cancer|July 25, 2018
Expert consensus on image-guided radiofrequency ablation of pulmonary tumors: 2018 editionBao-Dong Liu, Xin Ye, Wei-Jun Fan, et al.
Chinese Journal of Cancer|December 24, 2017
Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trialRui-Hua Xu, Lin Shen, Ke-Ming Wang, et al.
The Lancet. Oncology|April 20, 2023
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 studyJianming Xu, Ken Kato, Eric Raymond, et al.
Pageof 156